CRS: BJMC
Position: Sr. Finance Administrator, BJMC CRS
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
